Human umbilical cord blood plasma can replace fetal bovine serum for primary culture, proliferation and cryopreservation of umbilical cord mesenchymal stem cells

doi:10.3969/j.issn.2095-4344.2014.37.008

Abstract

Abstract:

BACKGROUND: Fetal bovine serum based media used for expanding and cryopreserving human mesenchymal stem cells raise safety concerns in the clinical setting.
OBJECTIVE: To investigate the feasibility of human umbilical cord blood plasma as a replacement for fetal bovine serum in culture and cryopreservation of human mesenchymal stem cells derived from umbilical cord.
METHODS: Umbilical cord blood units were suitable for this research if they fulfilled the donor selection criteria of the Guangzhou Cord Blood Bank strictly. Cord blood plasma was ready to use after collected from the plasma reduction during the suitable cord blood units processing and pooling. Umbilical cord mesenchymal stem cells were harvested from the umbilical cord tissue of health full-term newborns after delivery by enzyme digestion and were cultured in the presence of Dulbecco’s modified Eagle’s medium/Ham’s nutrient mixture F-12 containing either fetal bovine serum or pooled cord blood plasma. Morphology, proliferation, immunophenotype detected by flow cytometry and differentiation toward adipogenic and osteogenic lineages were utilized for investigating the effect of media on umbilical cord mesenchymal stem cells after 3-5 passages. Then cells were cryopreserved in media containing 10% dimethyl sulfoxide, 20% fetal bovine serum or 20% pooled cord blood plasma for at least 6 months. Viability, adhesion, proliferation, immunophenotype and osteogenic differentiation of the cells were assessed after thawing.
RESULTS AND CONCLUSION: The morphology (spindle-shaped and plastic-adherent), phenotype and differentiation potential (osteogenic and adipogenic) were almost indistinguishable between cells cultured in fetal bovine serum or cord blood plasma medium, while cells grown in cord blood plasma medium demonstrated significantly higher proliferation rates than those in medium containing fetal bovine serum. After thawing, the cells maintained their adherence to the culture surface and differentiation potential to osteoblasts, but cells from cord blood plasma cryopreservation medium showed significantly better plastic attachment and produced greater cell numbers than fetal bovine serum for the first three post-thaw passages. The results demonstrate that cord blood plasma can sever as an effective substitute to fetal bovine serum for growth, maintenance and differentiation of umbilical cord mesenchymal stem cells, and thus it will be a safe choice for clinical-scale production of human mesenchymal stem cells.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: fetal blood, plasma, umbilical cord, mesenchymal stem cells, freezing

CLC Number:

R394.2

Wu Jie-ying, Lu Yan, Chen Jin-song, Zhu Lu, Gan Wen-ting. Human umbilical cord blood plasma can replace fetal bovine serum for primary culture, proliferation and cryopreservation of umbilical cord mesenchymal stem cells[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(37): 5947-5954.

Figures/Tables 7

References

[1] Sharma RR, Pollock K, Hubel A,et al.Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.Transfusion. 2014;54(5):1418-1437.
[2] Salem HK, Thiemermann C.Mesenchymal stromal cells: current understanding and clinical status.Stem Cells. 2010; 28(3):585-596.
[3] Patel AN, Genovese J.Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy.Stem Cells Cloning. 2011;4:61-72.
[4] Chanda D, Kumar S, Ponnazhagan S.Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.J Cell Biochem. 2010;111(2):249-257.
[5] Schallmoser K, Rohde E, Reinisch A,et al.Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum.Tissue Eng Part C Methods. 2008;14(3):185-196.
[6] Prockop DJ."Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs).Clin Pharmacol Ther. 2007;82(3):241-243.
[7] Spees JL, Gregory CA, Singh H,et al.Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy.Mol Ther. 2004;9(5): 747-756.
[8] Mannello F, Tonti GA.Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold!Stem Cells. 2007; 5(7):1603-1609.
[9] Tekkatte C, Gunasingh GP, Cherian KM,et al."Humanized" stem cell culture techniques: the animal serum controversy. Stem Cells Int. 2011;2011:504723.
[10] Bieback K, Hecker A, Kocaömer A,et al.Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow.Stem Cells. 2009;27(9):2331-2341.
[11] Jung J, Moon N, Ahn JY,et al.Mesenchymal stromal cells expanded in human allogenic cord blood serum display higher self-renewal and enhanced osteogenic potential.Stem Cells Dev. 2009;18(4):559-571.
[12] 吴洁莹,廖灿,许遵鹏,等.广州脐血库造血干细胞保存及临床应用[J].中华生物医学工程杂志,2010,16(5): 438-443.
[13] Stolzing A, Jones E, McGonagle D,et al.Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies.Mech Ageing Dev. 2008; 129(3):163-173.
[14] Jung S, Panchalingam KM, Rosenberg L,et al. Ex vivo expansion of human mesenchymal stem cells in defined serum-free media.Stem Cells Int. 2012;2012:123030.
[15] Dahl JA, Duggal S, Coulston N,et al.Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum.Int J Dev Biol. 2008;52(8):1033-1042.
[16] Stute N, Holtz K, Bubenheim M,et al. Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use.Exp Hematol. 2004;32(12):1212-1225.
[17] Felka T, Schäfer R, De Zwart P,et al.Animal serum-free expansion and differentiation of human mesenchymal stromal cells.Cytotherapy. 2010;12(2):143-153.
[18] Turnovcova K, Ruzickova K, Vanecek V,et al. Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media.Cytotherapy. 2009;11(7):874-885.
[19] Poloni A, Maurizi G, Rosini V,et al.Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow. Cytotherapy. 2009;11(2):153-162.
[20] Tateishi K, Ando W, Higuchi C,et al.Comparison of human serum with fetal bovine serum for expansion and differentiation of human synovial MSC: potential feasibility for clinical applications.Cell Transplant. 2008;17(5):549-557.
[21] Le Blanc K, Samuelsson H, Lönnies L,et al. Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum.Transplantation. 2007;84(8):1055-1059.
[22] Flemming A, Schallmoser K, Strunk D,et al. Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate.J Clin Immunol. 2011;31(6):1143-1156.
[23] Cholewa D, Stiehl T, Schellenberg A,et al.Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density.Cell Transplant. 2011; 20(9):1409-1422.
[24] Trojahn Kølle SF, Oliveri RS, Glovinski PV,et al.Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use.Cytotherapy. 2013;15(9):1086-1097.
[25] Hemeda H, Giebel B, Wagner W.Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells.Cytotherapy. 2014;16(2):170-180.
[26] 吕江涛,田少奇,孙康,等.血小板裂解液对人脐带间充质干细胞体外成骨分化的影响[J].中国组织工程研究,2012,16(41): 7637-7641.
[27] Abdelrazik H, Spaggiari GM, Chiossone L,et al.Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function.Eur J Immunol. 2011;41(11):3281-3290.
[28] Phadnis SM, Joglekar MV, Venkateshan V,et al.Human umbilical cord blood serum promotes growth, proliferation, as well as differentiation of human bone marrow-derived progenitor cells.In Vitro Cell Dev Biol Anim. 2006;42(10): 283-286.
[29] Shetty P, Bharucha K, Tanavde V.Human umbilical cord blood serum can replace fetal bovine serum in the culture of mesenchymal stem cells.Cell Biol Int. 2007;31(3):293-298.
[30] 旷文勇,周新伏,李睿娟,等.脐带血清和成人自体血清体外培养人骨髓间充质干细胞的比较[J].中国组织工程研究与临床康复, 2009,13(45):8917-8921.
[31] 吴刚,何辉,曹月诚,等.不同血清培养条件下骨髓间充质干细胞的增殖[J].中国组织工程研究与临床康复,2010,14(49):9151- 9154.
[32] Murphy MB, Blashki D, Buchanan RM,et al.Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation.Biomaterials. 2012;33(21):5308-5316.
[33] 丁妍,卢智勇,袁雅红,等.脐血浆与胎牛血清培养人脐带间充质干细胞的比较[J]. 生物医学工程学杂志,2013,30(6):1279-1282.
[34] Dominici M, Le Blanc K, Mueller I,et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
[35] Horwitz EM, Le Blanc K, Dominici M,et al.Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.Cytotherapy. 2005;7(5):393-395.
[36] Hemeda H, Kalz J, Walenda G,et al.Heparin concentration is critical for cell culture with human platelet lysate.Cytotherapy. 2013;15(9):1174-1181.
[37] Jung S, Sen A, Rosenberg L,et al.Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells.Cytotherapy. 2010; 12(5): 637-657.
[38] Lindroos B, Boucher S, Chase L,et al.Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro.Cytotherapy. 2009;11(7):958-972.
[39] Liu CH, Wu ML, Hwang SM. Optimization of serum free medium for cord blood mesenchymal stem cells. Biochem Eng J. 2007; 33: 1-9.
[40] 周婷婷,卫超,陈晓东,等.无血清培养体系原代培养脐带间充质干细胞[J].中国组织工程研究,2013,17(27):4980-4987.